Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 24, 2017
Pharmacy Choice - News - Front Page Healthcare News - November 24, 2017

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/24/17 - Acasti Pharma Clarifies Term of Proposed Strategic Partnership with Leading China Pharmaceutical Company
Laval, Quebec, CANADA- Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, today clarified the proposed term of the transaction contemplated by its recently announced non-binding term sheet with a leadi
11/24/17 - Cerus Corporation Receives IDE Approval to Initiate Phase III ReCePI Study
By a News Reporter-Staff News Editor at Genomics& Genetics Weekly Cerus Corporation announced it has received an investigational device exemption approval from the U.S. Food and Drug Administration to initiate ReCePI. ReCePI is one of the three Phase III clinical trials we will be conducting to support our planned submission to the FDA for U.S. l
11/24/17 - Compulink Showcases Best-of-Breed EHR Technology for Ophthalmology at AAO 2017
Used by more than 10,000 providers nationwide, Compulink's MACRA-ready all-in-one system supports the entire practice workflow? This stamp of approval designates that Compulink's solutions offer functionality to help providers meet the ever-evolving clinical practice improvement and care coordination activities that are required for successful...
11/24/17 - Data from Harvard School of Medicine Provide New Insights into Internal Medicine (The Effects of Public Disclosure of Industry Payments to Physicians...
Data from Harvard School of Medicine Provide New Insights into Internal Medicine. According to news reporting originating from Boston, Massachusetts, by NewsRx correspondents, research stated, "Financial ties between physicians and the pharmaceutical and medical device industry are common, but little is known about how patient trust is affected by
11/24/17 - Data on Osteonecrosis Reported by Researchers at Hospital of Santa Maria (Relevant factors for treatment outcome and time to healing in...
Data on Osteonecrosis Reported by Researchers at Hospital of Santa Maria. By a News Reporter-Staff News Editor at Health& Medicine Week Current study results on Musculoskeletal Diseases and Conditions- Osteonecrosis have been published. According to news reporting out of Lisbon, Portugal, by NewsRx editors, research stated, "Risk factors for...
11/24/17 - Debiopharm International SA Launches Clinical Trials Website for Patients - patients.debiopharm.com
Lausanne, Switzerland- Debiopharm International SA, part of Debiopharm Group, a Swiss-based global biopharmaceutical company, announced today the launch of its new clinical trials website patients.debiopharm.com. The website provides patients and their caregivers with helpful information on Debiopharm's clinical trials and studies.
11/24/17 - Digital Therapeutics Market Forecast 2017-2027
Visiongain, a research firm, issued the following report:. Digital Therapeutics- our new study reveals trends, R&D progress, and predicted revenues Where is the Digital Therapeutics market heading? If you are involved in this sector you must read this newly updated report.
11/24/17 - Drugs agency relocating to Amsterdam [Tehran Times (Iran)]
The European Medicines Agency is to relocate from London to Amsterdam after Brexit. It beat competition from countries including Athens, Barcelona, Brussels, Copenhagen, Dublin, Helsinki, Porto, Sofia, Stockholm, Malta, Warsaw and Zagreb to become the EMA`s new host. The decision was met with concerns over the number of highly skilled jobs that wil
11/24/17 - Eleison Pharmaceuticals to Partner with China Oncology Focus Limited, an Affiliate of Lee's Pharmaceutical Holdings
Princeton, NJ; Hong Kong- Eleison Pharmaceuticals, Inc., a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, and China Oncology Focus Limited, a subsidiary of Lee's Pharmaceutical Holdings Ltd. have jointly announced that a partnership is formed, to develop and commercialize the pancreatic drug candidate...
11/24/17 - FDA approves first implanted lens that can be adjusted after cataract surgery [Tehran Times (Iran)]
The U.S. Food and Drug Administration today approved the RxSight Inc. Light Adjustable Lens and Light Delivery Device, the first medical device system that can make small adjustments to the artificial lens power after cataract surgery so that the patient will have better vision when not using glasses. Cataracts are a common eye condition where the
11/24/17 - FDA approves first implanted lens that can be adjusted after cataract surgery to improve vision without eyeglasses in some patients
The U.S. Food and Drug Administration today approved the RxSight Inc. Light Adjustable Lens and Light Delivery Device, the first medical device system that can make small adjustments to the artificial lens' power after cataract surgery so that the patient will have better vision when not using glasses. Cataracts are a common eye condition where the
11/24/17 - FDA approves first two-drug regimen for certain patients with HIV
The U.S. Food and Drug Administration today approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 instead of three or more drugs included in standard HIV treatment. 'Limiting the number of drugs in any HIV treatment regimen can help reduce toxicity for patien
11/24/17 - FDA approves medical system to adjust artificial lens after cataract surgery. [Sudan Tribune]
The lens and device are the first medical device system approved by the FDA to make small adjustments to the artificial lens after cataract surgery. The FDA approved the device after it passed the safety and efficacy clinical test on 600 patients. Until now, refractive errors that are common following cataract surgery could only be corrected with g
11/24/17 - Findings in the Area of Radiation Therapy Reported from Food and Drug Administration (Implementation of nanoparticles in therapeutic radiation...
Findings in the Area of Radiation Therapy Reported from Food and Drug Administration. According to news reporting originating from Silver Spring, Maryland, by NewsRx correspondents, research stated, "Development and progress of cancer is a very complex disease process to comprehend because of the multiple changes in cellular physiology, pathology,
11/24/17 - Flow Cytometers Medical Devices Pipeline Market Growth Opportunity and Industry Forecast 2017
Industry Overview This report gives us an overview of the Flow Cytometers - Medical Devices Pipeline Marketwhich is classified on the basis of product and its various applications. It also mentions the key area where the demand fo...
11/24/17 - Glenmark Pharmaceuticals receives ANDA approval for HAILEY TM Fe 1 20
Glenmark's current portfolio consists of 129 products authorized for distribution in the U.S. marketplace and 58 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio
11/24/17 - GSK Submits Landmark Impact Data to US Regulatory Authority to Support Expanded Label for Trelegy Ellipta
GlaxoSmithKline issued the following news release:. GlaxoSmithKline plc and Innoviva, Inc. today announced the filing of a supplemental New Drug Application with the US Food and Drug Administration for the use of Trelegy Ellipta for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patient
11/24/17 - Ignyta Announces Third Quarter 2017 Company Highlights and Financial Results
By a News Reporter-Staff News Editor at Drug Week Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, announced company highlights and financial results for the third quarter ended September 30, 2017. "We are pleased with the continued development and regulatory progress of our lead product candidate, entrectinib-an.
11/24/17 - Immungenetics AG initiates 'DrainAD' - a Phase II Clinical Study in Alzheimer's Disease
ROSTOCK, GERMANY/ ACCESSWIRE/ November 24, 2017/ Immungenetics AG, a German based biopharmaceutical company focusing on innovative treatments that address unmet medical needs in the field of neurodegenerative, autoimmune diseases and aging, announces the initiation of DrainAD, a Phase II proof-of-concept study for the diagnosis and therapy of...
11/24/17 - Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA, for the Treatment of HIV-1 Infection
TITUSVILLE, N.J- Janssen Therapeutics, Division of Janssen Products, LP, today announced that the U.S. Food and Drug Administration has approved JULUCA, the first, complete, single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 infection in certain adults living with the disease who are virologically suppressed.
11/24/17 - Janssen seeks European approval for expanded use of Darzalex in newly diagnosed MM [Sport360]
Janssen-Cilag International NV announced the submission of a Type II variation application to the European Medicines Agency, for the immunotherapy Darzalex. This submission to health authorities takes us one step closer to our goal of redefining combination therapy in multiple myeloma, with the potential to make daratumumab available to more patien
11/24/17 - Janssen Seeks Expanded Use of DARZALEX from EMA in Newly Diagnosed Multiple Myeloma
BEERSE, BELGIUM- Janssen-Cilag International NV today announced the submission of a Type II variation application to the European Medicines Agency, for the immunotherapy DARZALEX. 'This submission to health authorities takes us one step closer to our goal of redefining combination therapy in multiple myeloma, with the potential to make daratumumab.
11/24/17 - Janssen Submits Application to U.S. FDA to Expand Indication for DARZALEX Combination Therapy for Patients
RARITAN, NJ- Janssen Biotech, Inc. today announced that it has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration for DARZALEX. As part of the application, Janssen has requested Priority Review, which the FDA grants to investigational therapies that, if approved, may offer significant improvements in the
11/24/17 - Johns Hopkins University - Combination Low-Salt and Heart-Healthy 'Dash' Diet as Effective as Drugs for Some Adults With High Blood Pressure
Results of the randomized clinical trial of the dietary combination, conducted by researchers at the Johns Hopkins University School of Medicine, were published in the Nov. 12 issue of Journal of the American College of Cardiology. 'Our results add to the evidence that dietary interventions are as effective as-or more effective than-antihypertensiv
11/24/17 - Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy
Rehovot, Israel- Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today announced that the Company and Chiesi Farmaceutici S.p.A., a fully integrated European Pharmaceutical company focused on respiratory disease and special care products, have mutually agreed to terminate the parties' European distribution.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415